Other less common epigenetic-based combinations include BET inhibitors combined with FLT3 inhibitors, as well as DOT1L or menin inhibitors used alongside hypomethylating agents in the treatment of MLL-rearranged AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.